Stocks
Merck Stock Surges on Guggenheim Price Target Boost
Merck & Co.'s stock price rose after Guggenheim raised its price target to $170.00, citing strong oncology growth potential from the company's melanoma cancer vaccine collaboration with Moderna.
The new target represents a 16.44% increase from Guggenheim's previous target of $146.00, underscoring renewed confidence in Merck's long-term oncology pipeline.
Merck shares have been trading close to their 52-week high in recent sessions, reaching a price of $156.92 on August 25, 2026, with the current stock price at $148.44 as of September 8, 2026.